Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, ...
Novo Nordisk will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its ...
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
Shares in Amazon ( AMZN) are up nearly 46% over the past year, with the stock hitting a record high closing price of $238.15 (£191.84) on Tuesday. A key focus in Amazon's ( AMZN) upcoming results will ...
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...